[New - In The Fed’s Inflation Fight, Biotech May Be The First Casualty](https://wbbsec.com/opinions-and-features/)
[New - In The Fed’s Inflation Fight, Biotech May Be The First Casualty](https://wbbsec.com/opinions-and-features/)
powered by bulletin

04.08.2022 | Forbes

By Steve Brozak

These last ten days have been the most important in coming to an understanding of our Covid-19 vaccination strategy.

You can be forgiven if you don’t follow biomedical governmental machinations closely. What happened was this: Last week, without any input from the Food and Drug Administration (FDA)’s own Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA authorized a second booster dose of the Pfizer-BioNTech and Moderna Covid-19 vaccines for people over 50 and the immunocompromised.

Then, two days ago, the VRBPAC committee convened for a scheduled discussion about the future of Covid-19 vaccines. And for the first time, the public could witness, via its live-streamed meeting, a group of experts honestly addressing what has become the grim reality of our current strategy dealing with the Covid-19 pandemic. In a palpably concerned forum the panel members could be seen calculating the human expense of a continued vaccine strategy where we have reached an untenable every-four-months booster effort. It seemed that the VRBPAC was looking for a vision of pandemic resolution that was no longer possible through vaccine eyes and that another path was needed.

To read the entire article on Forbes, please click here…